Ondine Biomedical Inc. (OBI.L)
| Previous close | 5.88 |
| Open | 5.75 |
| Bid | 5.75 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 5.75 - 6.00 |
| 52-week range | 5.50 - 20.40 |
| Volume | |
| Avg. volume | 304,802 |
| Market cap | 13.322M |
| Beta (5Y monthly) | -0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.06 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ACCESSWIREOndine Biomedical Inc Announces New Study Confirms Nose Is Key Source of Infection
Findings include 86% of surgical site infections ("SSIs") caused by bacteria from the patients' own nose, skin, or gut and nearly 60% of infections are resistant to antibiotics VANCOUVER, BC / ACCESSWIRE / April 25, 2024 / Ondine Biomedical Inc. (LON:OBI), ...
- ACCESSWIRE
Ondine Biomedical Inc Announces Corporate and Trading Update
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon the ...
- ACCESSWIRE
Ondine Biomedical Inc Announces Steriwave in First Australian Hospital
Mater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedical's award-winning light-activated antimicrobial technology VANCOUVER, BC / ACCESSWIRE / April 22, 2024 / Ondine Biomedical Inc. (LSE:OBI), the Canadian life ...
